Drug Trial Radar · NCT07691242
Multiple Ascending Dose Study of DW4421
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Multiple Ascending Dose of DW4421, phase I
Conditions
- Healthy Adult Volunteers
Interventions
DW4421S-T0Drug
DW4421 5mg
DW4421S-T2Drug
DW4421 15mg
DW4421S-T1Drug
DW4421 20mg
DW4421S-T3Drug
DW4421 30mg
DW4421SDrug
DW4421 40mg
DW4421-3Drug
Zastaprazan 20mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCτ,ss, Area under the drug concentration-time curve of DW4421 following multiple oral administrationTime frame: Day 7
- Cmax of DW4421 following multiple oral administrationTime frame: Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.